Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
-$0.06 today
- Market cap
- $63.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
Volume 0.41M
Average 0.43M
FBIO Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Fortress Biotech, Inc.NASDAQ: FBIO
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin widens to 688.2%
Net margin was 688.2% in Q1 FY2026, up 768.8 pp from a year earlier. On a trailing-twelve-month basis it was 193.1%, up 264.4 pp year over year. Over 3 fiscal years it widened by 125.1 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 1 analysts of 121.4% for the fiscal year ending Dec 2026, up from 10.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 688.2%+712.7 pp QoQ
- Last fiscal yearDec 2025
- 10.8%+90.5 pp YoY
- LTMMar 2026
- 193.1%+264.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +768.8 pp | -131.2 pp | -900.0 pp |
| 1 year | +90.5 pp | +110.6 pp | +20.1 pp |
| 3 years | +125.1 pp | — | — |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 10.8%
- Year-over-year change
- +90.5pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.8% | +90.5pp |
| FY2024 | 2024-12-31 | -79.8% | -8.0pp |
| FY2023 | 2023-12-31 | -71.7% | +42.6pp |
| FY2022 | 2022-12-31 | -114.3% | -20.2pp |
| FY2021 | 2021-12-31 | -94.1% | — |
Net Margin vs competitors
How FBIO compares with its peers on the latest reported figures
- FBIO's LTM Mar 2026 net margin of 193.1% is the highest of the 5 companies compared; the peer median is -904.5%.
- Its year-over-year change of +264.4 pp is the 2nd highest of 4, against a peer median of +137.1 pp.
- Over three fiscal years its change of +125.1 pp compares with a peer median of +229.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 193.1% | +264.4 pp | +125.1 pp | |
| LTM Mar 2026 | 14.5% | +137.1 pp | +100715.3 pp | |
| LTM Apr 2026 | -448.4% | -32.6 pp | -172.7 pp | |
| LTM Mar 2026 | -1360.6% | +1613.5 pp | -767.6 pp | |
| LTM Jun 2024 | -3904.3% | — | +631.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding FBIO) | -904.5% | +137.1 pp | +229.1 pp | |
Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 68.79M | 75.74M | 84.51M | 57.68M | 63.26M |
| Cost of Revenue | 32.08M | 30.78M | 22.89M | 20.88M | 20.92M |
| Gross Profit | 36.71M | 44.97M | 61.62M | 36.8M | 42.34M |
| Gross Margin | 53.4% | 59.4% | 72.9% | 63.8% | 66.9% |
| Research & Development | 128.87M | 134.88M | 106.07M | 56.88M | 11.9M |
| Selling, General & Admin | 86.84M | 113.66M | 90.98M | 87.73M | 96.4M |
| Operating Expenses | 225.25M | 248.53M | 203.96M | 147.18M | 112.56M |
| Depreciation & Amortization | 6.79M | 9.35M | 6M | 4.46M | 4.66M |
| EBITDA | (146.17M) | (193.69M) | (135.72M) | (104.49M) | (20.17M) |
| EBITDA Margin | -212.5% | -255.7% | -160.6% | -181.2% | -31.9% |
| Operating Income | (188.54M) | (203.56M) | (142.34M) | (110.38M) | (70.22M) |
| Operating Margin | -274.1% | -268.8% | -168.4% | -191.4% | -111.0% |
| Interest Income | 649K | 1.4M | 3M | 2.68M | 2.49M |
| Interest Expense | 15.31M | 13.64M | 12.52M | 9.93M | 8.71M |
| Other Income / Expenses | 24.19M | (9.9M) | (11.29M) | (10.16M) | 36.69M |
| Income Before Tax | (164.35M) | (213.46M) | (153.63M) | (120.54M) | (33.54M) |
| Pre-Tax Margin | -238.9% | -281.8% | -181.8% | -209.0% | -53.0% |
| Income Tax Expense | 473K | 449K | 521K | 312K | (620K) |
| Net Income | (64.7M) | (86.58M) | (60.64M) | (46M) | 6.82M |
| Net Margin | -94.1% | -114.3% | -71.7% | -79.8% | 10.8% |
| EPS (Basic) | (11.85) | (14.55) | (8.47) | (2.69) | (0.07) |
| EPS (Diluted) | (11.85) | (14.55) | (8.47) | (2.69) | (0.07) |
| Weighted Avg Shares | 5.45M | 5.93M | 8.11M | 20.78M | 27.9M |
| Weighted Avg Shares (Diluted) | 5.45M | 5.93M | 8.11M | 20.78M | 279.02M |
Fortress Biotech, Inc.
NASDAQ:FBIO
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.